PRTK - Paratek Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

345.3M

Cash

42.69M

Avg Qtr Burn

-5.805M

Short % of Float

5.26%

Insider Ownership

11.70%

Institutional Own.

55.08%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Seysara (Sarecycline) Details Inflammatory Acne (Acne Vulgaris)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nuzyra (Omadacycline) Details ABSSSI (Acute bacterial skin and skin structure infections) - IV + Oral	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nuzyra (Omadacycline) Details Pneumonia, Community acquired bacterial pneumonia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Omadacycline (Nuzyra) Details Intestinal infection, Digestive tract, Stomach, Nontuberculous mycobacteria infections	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.